跳至主要内容
临床试验/NCT07053891
NCT07053891招募中不适用

LUPKYNIS Drug-use Results Survey

Otsuka Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2025年9月17日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
400
试验地点
1
主要终点
Safety Information (Number of Adverse Event)

研究概览

简要总结

The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are newly starting administration of LUPKYNIS for lupus nephritis

排除标准

  • 未提供

结局指标

主要结局

Safety Information (Number of Adverse Event)

时间窗: 3 years from the initiation of LUPKYNIS treatment

Any untoward medicinal occurrence in a patient or clinical study subject administered a Medicinal Product and which does not necessarily have a causal relationship with this treatment (ICH-E2A Guideline). An Adverse Event can therefore be any unfavorable and unintended sign (e.g. abnormal laboratory finding), symptom, or disease temporally associated with the use of a Medicinal Product (LUPKYNIS), whether or not it is considered causally related to the Medicinal Product.

Safety Information (Types of Special Situations and the Number of Corresponding Cases)

时间窗: 3 years from the initiation of LUPKYNIS treatment

Situations related to the use of an Otsuka product which may or may not be associated with an adverse event: * Maternal (pregnancy and breastfeeding) or paternal (via semen) exposure; * Exposure during breastfeeding; * Overdose/Incorrect dosage, misuse, abuse (e.g. patient sharing products); -Medication errors (e.g. patient took wrong dose); * Lack of therapeutic efficacy (e.g. the product doesn't work); * Occupational exposure (e.g.: nurse administering the product is exposed); * Cases of suspected transmission of infectious agents; * Use of suspected or confirmed falsified product(s) or quality defect of the product(s); * Withdrawal reactions; -Accidental exposure (e.g.: child takes parent's product); * Drug-drug/drug-food interactions; * Unintentional use of product in a non-approved population (e.g.: pediatric or geriatric population); * Disease progression/exacerbation of existing disease.

Safety Information (Number of off-Label Use)

时间窗: 3 years from the initiation of LUPKYNIS treatment

Collecting any type of off-Label Use that refers to situations where a product is intentionally used for a medical purpose not in accordance with the authorized product information. Off-label use also includes the intentional use in non-authorized population categories not indicated in the label.

Safety Information (Number of Serious Adverse Event)

时间窗: 3 years from the initiation of LUPKYNIS treatment

Any adverse drug experience/event occurring at any dose which * results in death * is life-threatening * requires inpatient hospitalization or prolonged of existing hospitalization * results in persistent or significant disability or incapacity * is a congenital anomaly/birth defect * is medically significant.

Safety Information (Number of Non-serious Adverse Events)

时间窗: 3 years from the initiation of LUPKYNIS treatment

All Adverse Events that do not meet the definition of a serious Adverse Event are considered non-serious Adverse Events.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验